AFM
SLS icon

Anson Funds Management’s SELLAS Life Sciences SLS Stock Holding History

Anson Funds Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2M Buy
+1,845,900
New +$12.7M 1.62% 13

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Anson Funds Management's SLS Position: Q2 2026 in Review

Anson Funds Management opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 4,500,000 shares worth $66.4M. The stake represents 3.94% of the portfolio and ranks #2 among its holdings. This is a return to the name: Anson Funds Management previously reported a position in SLS as recently as Q3 2025.

Anson Funds Management first reported a position in SLS in Q2 2019 and has held it in 8 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Anson Funds Management held 4,500,000 shares of SELLAS Life Sciences worth $66.4M as of Q2 2026.
  • SELLAS Life Sciences was a new Anson Funds Management position in Q2 2026.
  • SELLAS Life Sciences made up 3.94% of Anson Funds Management's portfolio in Q2 2026, its #2 holding.
  • Anson Funds Management first reported a position in SELLAS Life Sciences in Q2 2019 and has held it in 8 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Anson Funds Management's 13F filing for Q2 2026, filed 13 Aug 2026.